MarketBeat
21 Sept 2026, 00:02 UTC · 6w ago
Impact · against what's priced in
The news is largely neutral for Helus Pharma as it confirms existing expectations for a Q4 Phase III readout and a 2028 NDA filing. The detail regarding the adjunctive strategy for MDD clarifies the target market size but does not fundamentally change the risk-reward profile of the pipeline.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish · 0 new · 4 priced in
Helus Pharma expects a pivotal Phase III readout for its HLP003 program in adjunctive major depressive disorder in the fourth quarter.
Priced incomments made at Morgan Stanley conference
So whatA positive result would trigger a rolling NDA submission process aiming for 2028 approval.
More positive than 99% of claims this week
The company has guided to a potential New Drug Application (NDA) filing for HLP003 in 2028.
Continue reading
5 related stories
The company provides specific trial parameters for the APPROACH and EMBRACE studies, confirming a Q4 readout and a target 2028 approval via rolling submission.
Read from the article alone
Scored by the NIS engine · methodology.
Search tags
Priced instanding guidance mentioned by CEO
More positive than 76% of claims this week
Helus is finalizing the design of its next clinical trial for HLP004 in generalized anxiety disorder this quarter.
Priced incomments made at Morgan Stanley conference
So whatCompletion of the design this quarter is the prerequisite for initiating the next phase of testing for a 20-million-person US market.
More positive than 62% of claims this week
Helus expects to begin advancing a lead molecule from its HLP005 preclinical library in 2027.
Priced incomments made at Morgan Stanley conference
More positive than 40% of claims this week
Which stocks this story touches
More positive than 75% of ticker scores this week
The company is advancing multiple clinical-stage programs with positive Phase II data and upcoming Phase III readouts.
More positive than 47% of ticker scores this week
Mentioned in the context of expanding its CNS and psychedelic portfolio via acquisition.
More positive than 96% of relationship scores this week
[a_to_b] The article mentions Eli Lilly's acquisition of Atai.
More positive than 15% of relationship scores this week
[mutual] Both companies are developing psychedelic-based therapeutics for mental health conditions, specifically for major depressive disorder and generalized anxiety disorder.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
9h ago
−27.6%
Price is moving against the score
$8.96 vs $12.37 close before publication (Sep 18) · not market-adjusted
HELP chart →
